ArticleBlood neoplasia2025

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

Andrew D Zale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.